Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses

Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy and safety of tofacitinib in Brazilian patients from Phase 2 (P2) and Phase 3 (P3) global studies of up to 24 months' duration were evaluated. Data were pooled from Brazilian patients with RA...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medicine (Baltimore) 2018-08, Vol.97 (31), p.e11609-e11609
Hauptverfasser:	Lomonte, Andrea B.V., Radominski, Sebastião C., Marcolino, Flora M.D., Brenol, Claiton V., Zerbini, Cristiano A.F., García, Erika G., Akylbekova, Ermeg L., Rojo, Ricardo, de Leon, Dario Ponce
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Arthritis, Rheumatoid - blood Arthritis, Rheumatoid - drug therapy Blood Sedimentation - drug effects Brazil Clinical Trial/Experimental Study Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Female Humans Janus Kinase Inhibitors - administration & dosage Janus Kinase Inhibitors - adverse effects Male Methotrexate - administration & dosage Methotrexate - adverse effects Middle Aged Patient Reported Outcome Measures Piperidines - administration & dosage Piperidines - adverse effects Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrroles - administration & dosage Pyrroles - adverse effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!